The present invention relates to compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules may act as therapeutics.

Biomarkers, methods, devices, reagents, systems, and kits used to assess an individual for the prediction of risk of developing a primary or secondary Cardiovascular (CV) event over a 4 year period are provided.

A marker and product for auxiliary diagnosis of valvular heart disease (VHD) is provided. The present disclosure provides for the first time using PLAUR as a biomarker for auxiliary diagnosis of VHD. When the PLAUR is used for auxiliary diagnosis, the diagnostic result can be obtained in only one working day (high detection speed) with sensitivity/accuracy is much higher than the sensitivity/accuracy of NT-ProBNP and hsCRP, and a high-throughput operation is enabled.

Described herein is fatty acid-binding protein 3 (FABP3) and/or FABP4 for diagnosing or staging peripheral artery disease (PAD) or for assessing revascularization in PAD afflicted subjects. Also described is FABP3 and/or FABP4 for distinguishing PAD patients from non-PAD patients regardless of the presence PAD symptoms, for distinguishing PAD patients with a non-compressible ABI from non-PAD patients, or for determining prognosis in PAD. Also described herein are various methods and biomarker panels for use in PAD.

The present invention relates to a specific set of circulating biomarkers and related methods and kits for the diagnosis of Brugada Syndrome in a human being.

The present invention relates to a nanowell diagnostic kit for diagnosing a cardiovascular disease substance in blood, including: an electrode on which a plurality of nanowells are formed to accommodate a target substance; and a marker fixed to each of the plurality of nanowells of the electrode and responding to the target substance, wherein the target substance is identified through an electrochemical analysis method by applying a current to the electrode.

This disclosure relates to uses of 5-aminovaleric acid betaine and compositions related thereto. In certain embodiments, this disclosure relates to diagnostic assays and methods of measuring and monitoring 5-aminovaleric acid betaine levels or the ratio 5-aminovaleric acid betaine to carnitine in a sample. In certain embodiments, this disclosure relates to methods of treating or preventing muscle wasting comprising administering to a subject in need thereof an effective amount of 5-aminovaleric acid betaine, prodrug, or salt thereof

Antibodies which bind selectively to cardiac conduction system (CCS) cells, imaging and/or diagnostic reagents and compositions visualizing the CCS cells and therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention. Compositions and methods for isolation, purification, analyses and/or transplantation of the CCS cells, including pluripotent stem cell (hiPSC)-derived or human embryonic stem cell (hESC)-derived CCS cells.

The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

The present invention relates to a pharmaceutical composition and the like for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation, containing, as an active ingredient, an inhibitor of binding between CAP1 and PCSK9, an inhibitor of binding between CAP1 and resistin, or a CAP1 gene expression inhibitor. The present invention can lower the level of blood LDL-cholesterol by inhibiting the binding of CAP1 and PCSK9, the binding of CAP1 and resistin or the expression of a CAP1 gene. Therefore, the present invention can be effectively used as a pharmaceutical composition and the like for treating abnormal blood cholesterol levels and various cardiovascular diseases caused thereby, such as dyslipidemia, stroke, arteriosclerosis, and the like, and for inhibiting inflammation.